Patents Examined by Rita J. Desai
  • Patent number: 11028096
    Abstract: Various embodiments relate to a compound of the formula (I) and (II), wherein X, X1, X2, X3, and R1-R4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 8, 2021
    Assignee: Purdue Research Foundation
    Inventors: Arun K. Ghosh, Hiroaki Mitsuya, Prasanth Reddy Nyalapatla
  • Patent number: 11026936
    Abstract: Compounds of the formula I in which X, Q, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: June 8, 2021
    Assignee: Merck Patent GmbH
    Inventor: Hans-Peter Buchstaller
  • Patent number: 11014924
    Abstract: Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 25, 2021
    Assignee: CV6 Therapeutics (NI) Limited
    Inventors: Mark Spyvee, Robert D. Ladner
  • Patent number: 11008336
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof, formula (A).
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 18, 2021
    Assignee: Eli Lilly and Company
    Inventors: Christian Alexander Clarke, Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Rudyk, Selma Sapmaz, Ryan Edward Stites, Grant Mathews Vaught
  • Patent number: 11001564
    Abstract: The present invention includes novel substituted bicyclic (such as 4-substituted-chromane-8-carboxamide compounds), and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: May 11, 2021
    Assignee: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Steven Kultgen
  • Patent number: 10981898
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: April 20, 2021
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • Patent number: 10966963
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: April 6, 2021
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
  • Patent number: 10968215
    Abstract: The present invention provides a pyrido five-element aromatic ring compound, and a preparation method therefor and a use thereof. The compound provided in the present invention has an inhibitory effect on wild-type and/or mutant EZH2, and is well positioned to become a novel anti-tumor drug or a drug for the treatment of autoimmune diseases.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: April 6, 2021
    Assignees: SHANGHAI HAIHE PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Xuxing Chen, Meiyu Geng, Lei Jiang, Yi Chen, Jianhua Cao, Qingyun Jiang, Qianqian Shen, Jian Ding, Yucai Yao, Zhao Zhao, Yuanfang Xiong
  • Patent number: 10954233
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: March 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Phillip Alper, Jonathan Deane, Songchun Jiang, Tao Jiang, Thomas Knoepfel, Pierre-Yves Michellys, Daniel Mutnick, Wei Pei, Peter Syka, Guobao Zhang, Yi Zhang
  • Patent number: 10947231
    Abstract: Provided herein are improved processes for the synthesis of substituted tetrahydro beta-carboline derivatives. In particular, provided herein are improved processes useful for the preparation of (S)-4-chlorophenyl 6-chloro-1-(4-methoxyphenyl)-3,4-dihydro-1H-pyrido[3,4-b]indole-2(9H)-carboxylate.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: March 16, 2021
    Assignee: PTC Therapeutics, Inc.
    Inventors: Peter Seongwoo Hwang, Young-Choon Moon, Arasu Tamil, Hongyan Qi, Neil Almstead
  • Patent number: 10947234
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: March 16, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michelle R. Machacek, David J. Witter, Michael Hale Reutershan, Michael D. Altman, Paul Anthony Stupple
  • Patent number: 10941153
    Abstract: Embodiments of the present disclosure describe substituted phenethylamine derivatives, compositions comprising the substituted phenethylamine derivatives, methods of making the substituted phenethylamine derivatives, and methods of using the phenethylamine derivatives, and the like. Exemplary compounds of the present disclosure include compounds of the formula (I) and (II): wherein X, Ra, Rb, Rc, R1, R2, R3, and R4 are defined elsewhere.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: March 9, 2021
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Joseph John Topczewski, Matthew Ryan Porter
  • Patent number: 10941145
    Abstract: Compounds having a structure according to formula (I) where R1, R2, and R3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: March 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Sanjeev Gangwar, Prasanna Sivaprakasam, Shoshana L. Posy
  • Patent number: 10933056
    Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 2, 2021
    Assignees: Merck Sharp & Dohme Corp., MSD R&D (China) Co. Ltd.
    Inventors: John J. Acton, III, Jianming Bao, Melissa Egbertson, Xiaolei Gao, Scott T. Harrison, Sandra L. Knowles, Chunsing Li, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, Michael T. Rudd, Oleg B. Selyutin, David M. Tellers, Ling Tong, Jenny Miu-Chun Wai
  • Patent number: 10934279
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: March 2, 2021
    Assignee: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • Patent number: 10912769
    Abstract: Provided in the present invention are a 1-[(pyridin-3-yl-sulfonyl)-1h-pyrrol-3-yl] methanamine derivative having the structure shown below in formula (I) and a pharmaceutical composition and use thereof. The 1-[(pyridin-3-yl-sulfonyl)-1h-pyrrol-3-yl] methanamine derivative provided in the present invention has good gastric acid secretion inhibitory activities and excellent pharmacodynamic properties, while having relatively low toxicity.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: February 9, 2021
    Assignees: Jiangsu Jibeier Pharmaceutical Co. Ltd., Zhenjiang San An Pharmaceutical Co. Ltd.
    Inventors: Zhongyi Geng, Xinghai Chen
  • Patent number: 10906914
    Abstract: Compounds of Formula I and the pharmaceutically acceptable salts thereof are disclosed Formula I. The variables X1, X2, and R1-4 are disclosed herein. The compounds are useful for treating cancer and related proliferative diseases. Pharmaceutical compositions containing compounds of Formula I and methods of treatment comprising administering compounds of Formula I are also disclosed.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: February 2, 2021
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SUN YAT-SEN UNIVERSITY
    Inventors: Linkun An, Christophe Marchand, Yves Pommier
  • Patent number: 10898737
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Hiromichi Sugimoto, Takahiro Matsumoto
  • Patent number: 10882859
    Abstract: There are provided compounds of formula I, wherein X, Ak, s, A, R1 and R2 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of the JAK family) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: January 5, 2021
    Assignee: TOPIVERT PHARMA LIMITED
    Inventor: Matthew Colin Thor Fyfe
  • Patent number: 10865203
    Abstract: Provided herein are novel pyrazolo-quinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis; depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: December 15, 2020
    Assignees: UWM Research Foundation, Inc., Medical University of Vienna
    Inventors: James Cook, Daniel Knutson, Marko Mihovilovic, Laurin Wimmer